{"id":745594,"date":"2017-02-14T16:05:00","date_gmt":"2017-02-14T16:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/"},"modified":"2025-11-07T01:26:39","modified_gmt":"2025-11-07T06:26:39","slug":"mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/","title":{"rendered":"Merck\u2019s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial"},"content":{"rendered":"<p class=\"bwalignc\">       Data Presented at CROI Showed Doravirine Was Non-inferior to        Ritonavir-boosted Darunavir in Treatment-na\u00efve Adults after 48 weeks of        Treatment     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced results of a pivotal Phase 3 clinical trial evaluating<br \/>\n      the safety and efficacy of doravirine (MK-1439), an investigational<br \/>\n      non-nucleoside reverse transcriptase inhibitor (NNRTI). The study met<br \/>\n      its primary efficacy endpoint of the proportion of participants<br \/>\n      achieving levels of HIV-1RNA less than 50 copies\/mL after 48 weeks of<br \/>\n      treatment, demonstrating the non-inferiority of once-daily doravirine<br \/>\n      (DOR) to once-daily ritonavir-boosted darunavir (DRV+r), each<br \/>\n      administered with tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC)<br \/>\n      or abacavir\/lamivudine (ABC\/3TC), in previously untreated<br \/>\n      (treatment-na\u00efve) adults with HIV-1 infection. In addition, a secondary<br \/>\n      endpoint showed that the DOR-treated group had statistically significant<br \/>\n      lower levels of fasting low density lipoprotein cholesterol (LDL-C),<br \/>\n      versus the DRV+r group. Findings from the ongoing \u201cDRIVE-FORWARD\u201d Phase<br \/>\n      3 trial following 48 weeks of treatment were presented as a<br \/>\n      late-breaking abstract at the annual Conference on Retroviruses and<br \/>\n      Opportunistic Infections (CROI) being held in Seattle from Feb. 13-16,<br \/>\n      2017.\n    <\/p>\n<p>\n      \u201cImproved understanding of the biology of HIV and growing clinical<br \/>\n      evidence from current therapies are advancing the management of HIV<br \/>\n      infection,\u201d said Dr. Kathleen Squires, professor and director of<br \/>\n      infectious diseases, Thomas Jefferson University, Philadelphia. \u201cThe<br \/>\n      results of this study provide solid evidence of the efficacy and safety<br \/>\n      profile of doravirine as a potential treatment option for<br \/>\n      treatment-na\u00efve HIV-1 patients.\u201d\n    <\/p>\n<p>\n      <b>Data from DRIVE- FORWARD<\/b>\n    <\/p>\n<p>\n      In the trial, after 48 weeks of treatment, the proportion of<br \/>\n      participants achieving levels of HIV-1 RNA less than 50 copies\/mL<br \/>\n      following once-daily DOR (100 mg) or once-daily DRV+r (800 mg and 100 mg<br \/>\n      respectively), each in combination with either TDF\/FTC or ABC\/3TC, was<br \/>\n      83.8 percent (321\/383) and 79.9 percent (306\/383), respectively; with a<br \/>\n      treatment difference (95 % confidence interval) of 3.9 [-1.6, 9.4].<br \/>\n      Increases in mean CD4+ T-cell counts from baseline were similar for the<br \/>\n      DOR and DRV+r treatment groups: 193 and 186 cells\/mm<sup>3<\/sup>,<br \/>\n      respectively.\n    <\/p>\n<p>\n      In addition, comparable efficacy was observed for participants with<br \/>\n      baseline levels of HIV-1 RNA greater than 100,000 copies\/mL: 81.0<br \/>\n      percent (64\/79) for DOR and 76.4 percent (55\/72) for DRV+r; with a<br \/>\n      treatment difference (95% confidence interval) of 3.0 [-11.2, 17.1]. One<br \/>\n      out of 383 participants developed phenotypic and genotypic resistance in<br \/>\n      the DOR arm (the patient came off study at Week 24 because of<br \/>\n      non-adherence). None of the 383 participants receiving DRV+r developed<br \/>\n      phenotypic and genotypic resistance.\n    <\/p>\n<p>\n      The rates of reported adverse drug reactions were 31 percent (117\/383)<br \/>\n      for DOR and 32 percent (123\/383) for DRV+r. Discontinuations due to<br \/>\n      adverse events for the DOR and DRV+r treatment groups were 2 percent<br \/>\n      (6\/383) and 3 percent (12\/383), respectively. The most common adverse<br \/>\n      events for DOR and DRV+r (occurring in greater than or equal to 10<br \/>\n      percent of participants) were: diarrhea (14% vs. 22%); headache (14% vs.<br \/>\n      11%); nausea (11% vs. 12%) and nasopharyngitis (8% vs. 10 %),<br \/>\n      respectively.\n    <\/p>\n<p>\n      Analysis of fasting serum blood lipids for the DOR and DRV+r treated<br \/>\n      groups showed a statistically significant difference (p&lt;0.0001) in mean<br \/>\n      changes from baseline in the levels of LDL-C (-4.5 mg\/dL vs. +9.9 mg\/dL)<br \/>\n      and non-high density lipoprotein cholesterol (non-HDL-C) (-5.3 mg\/dL vs.<br \/>\n      +13.8 mg\/dL), respectively. Mean changes from baseline in total<br \/>\n      cholesterol, high density lipoprotein cholesterol (HDL-C) and<br \/>\n      triglycerides for the DOR- treated group and the DRV+r- treated group<br \/>\n      were -1.4 mg\/dL, +3.9 mg\/dL, and -3.1 mg\/dL vs. +17.9 mg\/dL, +4.2 mg\/dL,<br \/>\n      and +22 mg\/dL, respectively.\n    <\/p>\n<p>\n      \u201cMerck has been at the forefront of research into HIV for three<br \/>\n      decades,\u201d said Dr. George Hanna, associate vice president, clinical<br \/>\n      research, Merck Research Laboratories. \u201cWe are encouraged by these<br \/>\n      results, which provide additional insights into the efficacy and safety<br \/>\n      of doravirine.\u201d\n    <\/p>\n<p>\n      <b>About DRIVE-FORWARD<\/b>\n    <\/p>\n<p>\n      DRIVE-FORWARD is a multicenter, double-blind, randomized non-inferiority<br \/>\n      trial in which 769 treatment-na\u00efve adults with HIV-1 infection received<br \/>\n      either 100 mg doravirine or 800 mg darunavir plus 100 mg ritonavir, both<br \/>\n      administered orally once-daily in combination with either TDF\/FTC or<br \/>\n      ABC\/3TC. The primary endpoint of the clinical trial was the proportion<br \/>\n      of participants with HIV-1 RNA copies of less than 50 copies\/mL at Week<br \/>\n      48. There were a number of secondary endpoints, including an evaluation<br \/>\n      of the effects of DOR and DRV+r on fasting serum lipids, change from<br \/>\n      baseline in CD4+ T-cell count, and evaluation of safety and tolerability.\n    <\/p>\n<p>\n      For further information regarding DRIVE-FORWARD please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=51510036&amp;newsitemid=20170214006342&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=1&amp;md5=da3f9c4d8de652206bacffe33a10454f\" rel=\"nofollow\">www.clinicaltrials.gov<\/a><br \/>\n<span class=\"bwuline\"><br \/>\n      <\/span>clinical trial registry number NCT02275780.\n    <\/p>\n<p>\n      <b>About Doravirine<\/b>\n    <\/p>\n<p>\n      Doravirine is an investigational NNRTI being evaluated by Merck for the<br \/>\n      treatment of HIV-1 infection. In early clinical studies, doravirine<br \/>\n      demonstrated a pharmacokinetic profile supportive of once-daily dosing<br \/>\n      and the ability to be dosed with or without food.\n    <\/p>\n<p>\n      Doravirine is also being evaluated in several ongoing studies as a fixed<br \/>\n      dose single tablet regimen with 3TC and TDF (DOR\/3TC\/TDF). Phase 2<br \/>\n      studies include an evaluation of DOR\/3TC\/TDF in treatment-na\u00efve<br \/>\n      participants with transmitted resistance to NNRTIs and in people<br \/>\n      switching from efavirenz due to intolerability. Phase 3 studies include<br \/>\n      DRIVE-AHEAD, a trial comparing DOR\/3TC\/TDF to efavirenz\/ FTC\/TDF in<br \/>\n      treatment-na\u00efve participants, and DRIVE-SHIFT, a trial evaluating a<br \/>\n      switch to DOR\/3TC\/TDF in people who are currently virologically<br \/>\n      suppressed on another antiretroviral regimen.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For over a century, Merck has been a global health care leader working<br \/>\n      to help the world be well. Merck is known as MSD outside the United<br \/>\n      States and Canada. Through our prescription medicines, vaccines,<br \/>\n      biologic therapies, and animal health products, we work with customers<br \/>\n      and operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs, and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51510036&amp;newsitemid=20170214006342&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=8841665c27aeacd76fd7f06bdbf4f378\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51510036&amp;newsitemid=20170214006342&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=a0f1761082ed0425122f97bbfdd2c424\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51510036&amp;newsitemid=20170214006342&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=9df1f4869ab33117dd48b3338ec4f6ed\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51510036&amp;newsitemid=20170214006342&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=bf09642f1675e8232101d8bf88956780\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51510036&amp;newsitemid=20170214006342&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=ad467aa71ae6800b6bf2df610b8735dd\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51510036&amp;newsitemid=20170214006342&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=9862b10d60036b15d3ab9e265d2c53f1\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170214006342r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-246-5701<br \/>Carmen de Gourville,        267-664-0146<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-na\u00efve Adults after 48 weeks of Treatment Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). The study met its primary efficacy endpoint of the proportion of participants achieving levels of HIV-1RNA less than 50 copies\/mL after 48 weeks of treatment, demonstrating the non-inferiority of once-daily doravirine (DOR) to once-daily ritonavir-boosted darunavir (DRV+r), each administered with tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC) or abacavir\/lamivudine (ABC\/3TC), in previously untreated (treatment-na\u00efve) adults with HIV-1 infection. In addition, a secondary endpoint showed that the DOR-treated group had statistically significant lower levels of fasting low density<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745594","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-na\u00efve Adults after 48 weeks of Treatment Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). The study met its primary efficacy endpoint of the proportion of participants achieving levels of HIV-1RNA less than 50 copies\/mL after 48 weeks of treatment, demonstrating the non-inferiority of once-daily doravirine (DOR) to once-daily ritonavir-boosted darunavir (DRV+r), each administered with tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC) or abacavir\/lamivudine (ABC\/3TC), in previously untreated (treatment-na\u00efve) adults with HIV-1 infection. In addition, a secondary endpoint showed that the DOR-treated group had statistically significant lower levels of fasting low density\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\\\/\",\"name\":\"Merck\u2019s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-02-14T16:05:00+00:00\",\"dateModified\":\"2025-11-07T06:26:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial - Merck.com","og_description":"Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-na\u00efve Adults after 48 weeks of Treatment Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). The study met its primary efficacy endpoint of the proportion of participants achieving levels of HIV-1RNA less than 50 copies\/mL after 48 weeks of treatment, demonstrating the non-inferiority of once-daily doravirine (DOR) to once-daily ritonavir-boosted darunavir (DRV+r), each administered with tenofovir disoproxil fumarate\/emtricitabine (TDF\/FTC) or abacavir\/lamivudine (ABC\/3TC), in previously untreated (treatment-na\u00efve) adults with HIV-1 infection. In addition, a secondary endpoint showed that the DOR-treated group had statistically significant lower levels of fasting low density","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:39+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/","name":"Merck\u2019s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-02-14T16:05:00+00:00","dateModified":"2025-11-07T06:26:39+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-doravirine-an-investigational-non-nucleoside-reverse-transcriptase-inhibitor-nnrti-for-the-treatment-of-hiv-1-infection-met-primary-efficacy-endpoint-in-pivotal-phase-3-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"041066bc-a91d-46fa-9d27-3d1543b3cd4b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-Doravirine-an-Investigational-Non-Nucleoside-Reverse-Transcriptase-Inhibitor-NNRTI-for-the-Treatment-of-HIV-1-Infection-Met-Pr-GHXVQ.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745594\/revisions"}],"predecessor-version":[{"id":3674960,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745594\/revisions\/3674960"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745594"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}